sodium 1-amino-4-(3,5-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate

ID: ALA1671994

Chembl Id: CHEMBL1671994

PubChem CID: 53318846

Max Phase: Preclinical

Molecular Formula: C22H17N2NaO5S

Molecular Weight: 422.46

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(C)cc(Nc2cc(S(=O)(=O)[O-])c(N)c3c2C(=O)c2ccccc2C3=O)c1.[Na+]

Standard InChI:  InChI=1S/C22H18N2O5S.Na/c1-11-7-12(2)9-13(8-11)24-16-10-17(30(27,28)29)20(23)19-18(16)21(25)14-5-3-4-6-15(14)22(19)26;/h3-10,24H,23H2,1-2H3,(H,27,28,29);/q;+1/p-1

Standard InChI Key:  VWNCUXDSJPRQNU-UHFFFAOYSA-M

Associated Targets(Human)

P2RY4 Tchem Pyrimidinergic receptor P2Y4 (598 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P2RY12 Tclin Purinergic receptor P2Y12 (2369 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

P2rx2 P2X purinoceptor 2 (106 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P2rx4 P2X purinoceptor 4 (106 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 422.46Molecular Weight (Monoisotopic): 422.0936AlogP: 3.65#Rotatable Bonds: 3
Polar Surface Area: 126.56Molecular Species: ACIDHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: -2.73CX Basic pKa: CX LogP: 4.03CX LogD: 3.31
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.34Np Likeness Score: -0.36

References

1. Baqi Y, Hausmann R, Rosefort C, Rettinger J, Schmalzing G, Müller CE..  (2011)  Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.,  54  (3): [PMID:21207957] [10.1021/jm1012193]
2. Rafehi M, Malik EM, Neumann A, Abdelrahman A, Hanck T, Namasivayam V, Müller CE, Baqi Y..  (2017)  Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor.,  60  (7): [PMID:28306255] [10.1021/acs.jmedchem.7b00030]
3. Al-Najjar BO, Saqallah FG, Abbas MA, Al-Hijazeen SZ, Sibai OA..  (2022)  P2Y12 antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies.,  227  [PMID:34731765] [10.1016/j.ejmech.2021.113924]

Source